☆ 4.7 Meeting Abstract

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

BLOOD (2019)

Journal

BLOOD

Volume 134, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2019-125327

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Jonas S. Heitmann, Richard F. Schlenk, Daniela Doerfel, Sabine Kayser, Konstanze Doehner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Maerklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Grosse-Hovest, Martin Steiner, Gundram Jung, Helmut R. Salih

Summary: This study evaluated the safety, tolerability, pharmacokinetics and preliminary efficacy of FLYSYN antibody in AML patients with measurable residual disease (MRD). The results showed that FLYSYN monotherapy is safe and well-tolerated, with promising early efficacy data.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Oncology

Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation

Hong Wang, Xue-Qian Li, Tian-Tian Chu, Shi-Yu Han, Jia-Qian Qi, Ya-Qiong Tang, Hui-Ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, Chang-Geng Ruan, De-Pei Wu, Yue Han

Summary: Genetic changes play a prognostic role in CN-AML, with FLT3-ITD mutation and CEBPA(wt) being identified as independent risk factors associated with poor OS and DFS. HSCT significantly improves the prognosis of standard/high risk CN-AML patients, especially in those with combined CEBPA and FLT3-ITD mutations. Integration of molecular marker analyses and MRD assessment before transplantation can help predict patient outcomes in HSCT-treated patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk

Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.

CANCERS (2021)

Add to Collection

Article Multidisciplinary Sciences

MicroRNA networks in FLT3-ITD acute myeloid leukemia

Dinh Hoa Hoang, Dandan Zhao, Sergio Branciamore, Davide Maestrini, Ivan R. Rodriguez, Ya-Huei Kuo, Russell Rockne, Samer K. Khaled, Bin Zhang, Le Xuan Truong Nguyen, Guido Marcucci

Summary: In acute myeloid leukemia (AML), FLT3-ITD regulates the biogenesis of miR-126 and miR-155. FLT3-ITD induces the expression of miR-155, which down-regulates SHIP1 and increases AKT activity, leading to increased cell cycle progression. Additionally, miR-155 down-regulates SPRED1 and blocks the biogenesis of miR-126, resulting in decreased levels of mature miR-126.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Oncology

FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing

Jong-Mi Lee, Silvia Park, Insik Hwang, Dain Kang, Byung Sik Cho, Hee-Je Kim, Ari Ahn, Myungshin Kim, Yonggoo Kim

Summary: This article presents an ITD-tracing algorithm based on NGS method for monitoring MRD in AML patients. The assay shows high sensitivity and superior performance, and demonstrates prognostic value in AML patients undergoing allogeneic hematopoietic stem cell transplantation.

CANCERS (2022)

Add to Collection

Review Oncology

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection

Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty

Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.

CANCERS (2023)

Add to Collection

Article Oncology

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells

Yi Liu, Jing Wei, Jiaxin Liu, Weina Ma, Yanting Duan, Daihong Liu

Summary: The study investigated the upregulation of AXL antigen expression in FLT3-ITD+ AML blast cells, as well as the cytotoxic effects of novel AXL-targeted agents on FLT3-mutant AML cell lines and blast cells. Combinations of AXL-targeted agents with AC220 showed synergistic cytotoxic effects and induced apoptosis in FLT3 inhibitor-resistant blast cells. The antileukemic effect of AXL-targeted agents may rely on their ability to block AXL, FLT3 and their downstream signaling pathways.

ONCOLOGY LETTERS (2021)

Add to Collection

Article Oncology

UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia

Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak

Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.

CANCERS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway

Fangfang Wang, Jingcao Huang, Tingting Guo, Yuhuan Zheng, Li Zhang, Dan Zhang, Fujue Wang, Duolan Naren, Yushan Cui, Xiaoyan Liu, Ying Qu, Hongmei Luo, Yan Yang, Haichen Wei, Yong Guo

Summary: The combination treatment of HHT with quizartinib has shown synergistic effects on inhibiting cell growth, inducing apoptosis, and prolonging survival in mice with FLT3-ITD AML, suggesting it as a promising therapeutic strategy.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Review Oncology

CPX-351 in FLT3-mutated acute myeloid leukemia

Claire Andrews, Vinod Pullarkat, Christian Recher

Summary: CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been approved for treating newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In clinical trials, CPX-351 significantly improved overall survival in high-risk or secondary AML patients aged 60-75 years. FLT3 gene mutations are found in approximately 30% of newly diagnosed AML patients and may have a negative impact. CPX-351 combined with FLT3 inhibitors shows promise as a treatment option for FLT3 mutation-positive AML patients.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia

Zhou Yu, Jiaying Du, Hui Hui, Shaoxin Kan, Tongxin Huo, Kai Zhao, Tao Wu, Qinglong Guo, Na Lu

Summary: The study identified LT-171-861 as a potent FLT3 inhibitor and demonstrated its antitumor effects in AML, providing a rationale for future clinical trials in AML patients with FLT3-ITD mutations.

THERANOSTICS (2021)

Add to Collection

Article Medicine, Research & Experimental

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation

Dan Xu, Yishan Chen, Ying Yang, Zhao Yin, Changfen Huang, Qiang Wang, Ling Jiang, Xuejie Jiang, Changxin Yin, Qifa Liu, Guopan Yu

Summary: Autophagy plays a critical role in drug resistance in FLT3-ITD-positive AML. It can be activated by acquired mutation or bone marrow micro-environment (BME) and mediates resistance to FLT3 inhibitors. Inhibiting autophagy could be a promising strategy to overcome resistance.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia

Moo-Kon Song, Byeong-Bae Park, Ji-Eun Uhm

Summary: FLT3 mutations are the most common genetic alterations in AML and have a negative impact on clinical prognosis. The development of FLT3 inhibitors has shown promise in improving outcomes for AML patients with FLT3 mutations. Midostaurin and gilteritinib have recently been approved as frontline treatments for AML by the FDA. Clinical trials are ongoing to explore the use of FLT3 inhibitors in different treatment settings. The accumulation of data on FLT3 inhibitors will be important evidence for guiding the use of these inhibitors in AML patients with FLT3 mutations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis

Hui Zhang, Chaoke Bu, Zhiyong Peng, Guangchao Li, Zhao Zhou, Wen Ding, Yongwei Zheng, Yingyi He, Zhengbin Hu, Kunlin Pei, Min Luo, Chunfu Li

Summary: This study conducted a clinical trial of autologous anti-CLL1 CAR-T cell immunotherapy in children with relapsed or refractory AML to evaluate the safety and preliminary efficacy of the treatment. The results showed that anti-CLL1 CAR-T cell immunotherapy exhibited good tolerance and effectiveness for treating children with R/R-AML.

LEUKEMIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody

Marit J. van Elsas, Johan M. S. van der Schoot, Alexander Bartels, Kas Steuten, Duco van Dalen, Zacharias Wijfjes, Carl G. Figdor, Thorbald van Hall, Sjoerd H. van der Burg, Martijn Verdoes, Ferenc A. Scheeren

Summary: Regulatory T cells play a crucial role in immune suppression and pose challenges in cancer therapy. By optimizing the Fc domain of an antibody, efficient depletion of tumor-resident regulatory T cells can be achieved. Using a genome engineering strategy, a stable cell line producing optimized antibodies was generated, leading to effective depletion of tumor-resident regulatory T cells and enhanced tumor eradication when combined with other antibodies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Hematology

Identification of CD318 (CDCP1) as novel prognostic marker in AML

Jonas S. Heitmann, Ilona Hagelstein, Clemens Hinterleitner, Malte Roerden, Gundram Jung, Helmut R. Salih, Melanie Maerklin, Joseph Kauer

ANNALS OF HEMATOLOGY (2020)

Add to Collection

Article Cell Biology

Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cells

Melanie Maerklin, Jonas S. Heitmann, Joseph Kauer, Stefan Wirths, Martin R. Mueller

CELLULAR IMMUNOLOGY (2020)

Add to Collection

Article Hematology

CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation

Melanie Maerklin, Ilona Hagelstein, Clemens Hinterleitner, Helmut R. Salih, Joseph Kauer, Jonas S. Heitmann

INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Cell Biology

A novel flow cytometry-based assay to measure compromised B cell receptor signaling as a prognostic factor in chronic lymphocytic leukemia

Jonas S. Heitmann, Melanie Maerklin, Felicia M. Truckenmueller, Clemens Hinterleitner, Daniela Doerfel, Michael Haap, Hans-Georg Kopp, Stefan Wirths, Martin R. Mueller

JOURNAL OF LEUKOCYTE BIOLOGY (2020)

Add to Collection

Article Oncology

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Joseph Kauer, Sebastian Hoerner, Lukas Osburg, Stefanie Mueller, Melanie Maerklin, Jonas S. Heitmann, Latifa Zekri, Hans-Georg Rammensee, Helmut R. Salih, Gundram Jung

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Medicine, Research & Experimental

Oral intake of lipopolysaccharide regulates toll-like receptor 4-dependent granulopoiesis

Melanie Maerklin, Stefanie Bugl, Stefan Wirths, Julia-Stefanie Frick, Martin R. Mueller, Hans-Georg Kopp, Dominik Schneidawind

EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Article Oncology

Fc gamma receptor expression serves as prognostic and diagnostic factor in AML

Jonas S. Heitmann, Ilona Hagelstein, Clemens Hinterleitner, Lukas Osburg, Helmut R. Salih, Joseph Kauer, Melanie Maerklin

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Cell Biology

C-Cbl regulates c-MPL receptor trafficking and its internalization

Melanie Maerklin, Claudia Tandler, Hans-Georg Kopp, Kyle L. Hoehn, Leticia Quintanilla-Martinez, Oliver Borst, Martin R. Mueller, Sebastian J. Saur

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

Add to Collection

Article Immunology

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Annika Nelde, Tatjana Bilich, Jonas S. Heitmann, Yacine Maringer, Helmut R. Salih, Malte Roerden, Maren Luebke, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hoerber, Bjoern Traenkle, Philipp D. Kaiser, Ulrich Rothbauer, Matthias Becker, Daniel Junker, Gerard Krause, Monika Strengert, Nicole Schneiderhan-Marra, Markus F. Templin, Thomas O. Joos, Daniel J. Kowalewski, Vlatka Stos-Zweifel, Michael Fehr, Armin Rabsteyn, Valbona Mirakaj, Julia Karbach, Elke Jaeger, Michael Graf, Lena-Christin Gruber, David Rachfalski, Beate Preuss, Ilona Hagelstein, Melanie Maerklin, Tamam Bakchoul, Cecile Gouttefangeas, Oliver Kohlbacher, Reinhild Klein, Stefan Stevanovic, Hans-Georg Rammensee, Juliane S. Walz

Summary: SARS-CoV-2-specific T cell epitopes were identified in convalescent and unexposed individuals, showing cross-reactivity with common cold coronaviruses. The diversity of SARS-CoV-2 T cell responses may be associated with mild symptoms of COVID-19.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia

Melanie Maerklin, Alexander R. Fuchs, Claudia Tandler, Jonas S. Heitmann, Helmut R. Salih, Joseph Kauer, Leticia Quintanilla-Martinez, Stefan Wirths, Hans-Georg Kopp, Martin R. Mueller

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer

Latifa Zekri, Fabian Vogt, Lukas Osburg, Stefanie Mueller, Joseph Kauer, Timo Manz, Martin Pfluegler, Andreas Maurer, Jonas S. Heitmann, Ilona Hagelstein, Melanie Maerklin, Sebastian Hoerner, Tilmann Todenhoefer, Carsten Calaminus, Arnulf Stenzl, Bernd Pichler, Christian laFougere, Marc A. Schneider, Hans-Georg Rammensee, Lars Zender, Bence Sipos, Helmut R. Salih, Gundram Jung

Summary: The PSMA antibody 10B3 exhibits superior dual reactivity on prostate carcinoma and squamous cell carcinoma tissues, and is used to construct T-cell recruiting bispecific antibodies IgGsc, which show better efficacy in eliminating tumors. Treatment with IgGsc in three patients with metastasized prostate carcinoma resulted in significant T-cell activation and rapid reduction of elevated PSA levels.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection

Article Oncology

Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome

Malte Roerden, Melanie Maerklin, Helmut R. Salih, Wolfgang A. Bethge, Reinhild Klein, Hans-Georg Rammensee, Annika Nelde, Juliane S. Walz

Summary: Low human leukocyte antigen (HLA)-DR expression does not affect the diversity of antigen presentation in non-promyelocytic acute myeloid leukemia (AML) patients, and is not associated with survival rates.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Multidisciplinary Sciences

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Matthias Becker, Monika Strengert, Daniel Junker, Philipp D. Kaiser, Tobias Kerrinnes, Bjoern Traenkle, Heiko Dinter, Julia Haering, Stephane Ghozzi, Anne Zeck, Frank Weise, Andreas Peter, Sebastian Hoerber, Simon Fink, Felix Ruoff, Alex Dulovic, Tamam Bakchoul, Armin Baillot, Stefan Lohse, Markus Cornberg, Thomas Illig, Jens Gottlieb, Sigrun Smola, Andre Karch, Klaus Berger, Hans-Georg Rammensee, Katja Schenke-Layland, Annika Nelde, Melanie Maerklin, Jonas S. Heitmann, Juliane S. Walz, Markus Templin, Thomas O. Joos, Ulrich Rothbauer, Gerard Krause, Nicole Schneiderhan-Marra

Summary: The humoral immune response to SARS-CoV-2 is crucial for understanding COVID-19 progression, monitoring seroconversion, and supporting vaccine development. A multiplex immunoassay has been developed, including spike and nucleocapsid proteins of SARS-CoV-2 and endemic human coronaviruses, with high specificity and sensitivity.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia

Fabian Riegg, Martina S. Lutz, Bastian J. Schmied, Jonas S. Heitmann, Manon Queudeville, Peter Lang, Gundram Jung, Helmut R. Salih, Melanie Maerklin

Summary: B cell acute lymphoblastic leukemia (B-ALL) is characterized by malignant B cells and new therapeutic option like 293C3-SDIE, which targets CD133 on B-ALL cells, activates natural killer cells, leading to B-ALL cell lysis. CD133 could serve as a separate target in B-ALL therapy, providing a promising treatment option.

CANCERS (2021)

Add to Collection

Meeting Abstract Hematology

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, Daniela Dorfel, Sabine Kayser, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Wolfgang Bethge, Ludger Grosse-Hovest, Martin Steiner, Melanie Marklin, Juliane S. Walz, Richard F. Schlenk, Gundram Jung, Helmut R. Salih

BLOOD (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.